The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

August 4, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The phase 3 IXORA-S trial (NCT02561806) evaluated the efficacy of ixekizumab vs. ustekinumab for treating nail psoriasis and achieving skin clearance in patients with moderate to severe plaque psoriasis.1

You Might Also Like
  • Tofacitinib Treatment May Improve Nail Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
Also By This Author
  • Canada & E.U. Approve Upadacitinib for RA

During this double-blind, multicenter study, patients were randomized to receive either ixekizumab or ustekinumab. Patients who received ixekizumab (n=136) were given a 160 mg of ixekizumab starting dose, administered as two 80 mg injections. They next received 80 mg of ixekizumab every two weeks for 12 weeks, followed by 80 mg of ixekizumab administered every four weeks. Patients who received ustekinumab (n=166) were given an initial 45 or 90 mg dose of ustekinumab, calculated on the basis of their weight, and at weeks 0, 4 and every 12 weeks thereafter. Both dosing regimens lasted for a total of 52 weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers assessed the percentage of patients who achieved a score of 0 on the Nail Psoriasis Severity Index (NAPSI), as well as the NAPSI score change from baseline. The Psoriasis Area of Severity Index (PASI) and NAPSI improvement over the 52-week study were also assessed.

Results
Overall, patients with nail psoriasis had higher baseline PASI scores and longer a duration of plaque psoriasis than patients without nail psoriasis. At baseline, the mean NAPSI scores were 28.3 in the ixekizumab-treated group and 24.8 in the ustekinumab-treated group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In both treatment groups, progressive improvement occurred over the study period. However, by week 16, more patients taking ixekizumab achieved a NAPSI score of 0 (31%) than those taking ustekinumab (16%). This was statistically significant, and patients saw continued improvement. Additionally, more patients with significant baseline nail psoriasis achieved complete resolution (26%) with ixekizumab treatment than with ustekinumab treatment (10%) by week 20. Similar results were observed for NAPSI score improvement from baseline to week 52. At week 52, the NAPSI zero scores occurred in 61.9% of ixekizumab-treated patients and 28.6% of ustekinumab-treated patients (P< 0.001).

Additionally, ustekinumab-treated patients experienced a lower rate of plaque psoriasis skin clearance if they had nail psoriasis compared with ustekinumab-treated patients who did not have nail psoriasis. This finding was not the same for ixekizumab-treated patients. Ixekizumab-treated patients had similar skin responses throughout the treatment period whether or not nail psoriasis was present. At week 52, the percentage of patients who still had nail psoriasis was 7.8% in the ixekizumab group and 21.5% in the ustekinumab group.

Nail psoriasis is difficult to treat. This studied showed that ixekizumab was more effective than ustekinumab in clearing both nail and plaque psoriasis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Wasel N, Thaçi D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate to severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020 Aug;10(4):663–670.

Pages: 1 2 | Multi-Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: ixekizumab, nail psoriasis, Psoriasis, ustekinumab

You Might Also Like:
  • Tofacitinib Treatment May Improve Nail Psoriasis
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)